---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-031840"
form_type: "8-K"
ticker: "TNON"
cik: "0001560293"
company_name: "Tenon Medical, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:37:30.429310+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenon Medical Q4 revenue $1.5M (+92% YoY); full year $3.9M (+20%); FDA clearance for next-gen SI fusion system

## Summary
- Q4 revenue $1.5M (+92% YoY); gross margin improved to 69% from 46%.
- Full year 2025 revenue $3.9M (+20% YoY); gross margin 60%, up from 52%.
- Net loss improved: Q4 loss $2.8M ($0.29/sh) vs $3.1M ($0.98/sh); full year loss $12.6M ($1.70/sh) vs $13.7M ($11.26/sh).
- Received FDA 510(k) clearance for SImmetry+ SI Joint Fusion System, expanding to lateral approach.
- Closed $4.3M convertible note offering in March 2026; cash $3.8M at year-end, no debt.

## SEC filing metadata
- accession: 0001213900-26-031840
- form_type: 8-K
- ticker: TNON
- cik: 0001560293
- company_name: Tenon Medical, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1560293/000121390026031840/0001213900-26-031840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1560293/000121390026031840/ea0282552-8k_tenon.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-031840
- JSON: https://secwatch.observer/filing/0001213900-26-031840.json
- Plain text: https://secwatch.observer/filing/0001213900-26-031840.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.